Header Logo

GOLDY C GEORGE

TitleInstructor
InstitutionMD Anderson
DepartmentSymptom Research CAO
Address1515 Holcombe Blvd.
Houston TX 77030
vCardDownload vCard

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Li Sucholeiki R, Propst CL, Hong DS, George GC. Intermittent fasting and its impact on toxicities, symptoms and quality of life in patients on active cancer treatment. Cancer Treat Rev. 2024 Mar 28; 126:102725. PMID: 38574507.
      Citations:    Fields:    
    2. Mendoza TR, Hong DS, Peterson CB, Stephen B, Dumbrava E, Pant S, Tsimberidou AM, Yap TA, Sheshadri A, Altan M, George G, Castillo L, Rodriguez E, Gong J, Subbiah V, Janku F, Fu S, Piha-Paul SA, Ahnert JR, Karp DD, Cleeland C, Meric-Bernstam F, Naing A. Patient-reported symptom burden in patients with rare cancers receiving pembrolizumab in a phase II Clinical Trial. Sci Rep. 2022 08 23; 12(1):14367. PMID: 35999229; PMCID: PMC9399082.
      Citations:    
    3. Kim AJ, Hong DS, George GC. Dietary influences on symptomatic and non-symptomatic toxicities during cancer treatment: A narrative review. Cancer Treat Rev. 2022 Jul; 108:102408. PMID: 35623220.
      Citations:    Fields:    Translation:Humans
    4. Son J, George GC, Nardo M, Krause KJ, Jazaeri AA, Biter AB, Hong DS. Adoptive cell therapy in gynecologic cancers: A systematic review and meta-analysis. Gynecol Oncol. 2022 06; 165(3):664-670. PMID: 35400527; PMCID: PMC9133136.
      Citations:    Fields:    Translation:HumansCells
    5. Huey RW, George GC, Phillips P, White R, Fu S, Janku F, Karp DD, Naing A, Piha-Paul S, Subbiah V, Tsimberidou AM, Pant S, Yap TA, Rodon J, Meric-Bernstam F, Shih YT, Hong DS. Patient-Reported Out-of-Pocket Costs and Financial Toxicity During Early-Phase Oncology Clinical Trials. Oncologist. 2021 07; 26(7):588-596. PMID: 33783054; PMCID: PMC8265355.
      Citations: 3     Fields:    Translation:HumansCTClinical Trials
    6. Kim AJ, Hong DS, George GC. Diet-related interventions for cancer-associated cachexia. J Cancer Res Clin Oncol. 2021 May; 147(5):1443-1450. PMID: 33718995.
      Citations: 4     Fields:    Translation:HumansAnimals
    7. Mendoza T, Sheshadri A, Altan M, Hess K, George G, Stephen B, Castillo L, Rodriguez E, Gong J, Peterson C, Rodon Ahnert J, Fu S, Piha-Paul SA, Pant S, Dumbrava E, Yap TA, Janku F, Tsimberidou AM, Subbiah V, Karp DD, Zarifa A, McQuinn LM, Cleeland C, Hong DS, Naing A. Evaluating the psychometric properties of the Immunotherapy module of the MD Anderson Symptom Inventory. J Immunother Cancer. 2020 10; 8(2). PMID: 33097611; PMCID: PMC7590372.
      Citations: 3     Fields:    Translation:Humans
    8. Atkins JT, George GC, Hess K, Marcelo-Lewis KL, Yuan Y, Borthakur G, Khozin S, LoRusso P, Hong DS. Pre-clinical animal models are poor predictors of human toxicities in phase 1 oncology clinical trials. Br J Cancer. 2020 11; 123(10):1496-1501. PMID: 32868897; PMCID: PMC7652903.
      Citations: 2     Fields:    Translation:HumansAnimals
    9. George GC, Mendoza TR, Iwuanyanwu EC, Manandhar M, Afshar SF, Piha-Paul SA, Tsimberidou A, Naing A, Cleeland CS, Hong DS. Factors affecting symptom presentation in an early-phase clinical trials clinic patient population. Invest New Drugs. 2020 08; 38(4):1166-1174. PMID: 31761957; PMCID: PMC7919140.
      Citations:    Fields:    Translation:Humans
    10. George GC, Barata PC, Campbell A, Chen A, Cortes JE, Hyman DM, Jones L, Karagiannis T, Klaar S, Le-Rademacher JG, LoRusso P, Mandrekar SJ, Merino DM, Minasian LM, Mitchell SA, Montez S, O'Connor DJ, Pettit S, Silk E, Sloan JA, Stewart M, Takimoto CH, Wong GY, Yap TA, Cleeland CS, Hong DS. Improving attribution of adverse events in oncology clinical trials. Cancer Treat Rev. 2019 Jun; 76:33-40. PMID: 31108240.
      Citations: 8     Fields:    Translation:Humans
    11. George GC, Iwuanyanwu EC, Buford AS, Piha-Paul SA, Subbiah V, Fu S, Karp DD, Pant S, Hinojosa CO, Hess KR, Cleeland CS, Bernstam EV, Meric-Bernstam F, Hong DS. Cancer-Related Internet Use and Its Association With Patient Decision Making and Trust in Physicians Among Patients in an Early Drug Development Clinic: A Questionnaire-Based Cross-Sectional Observational Study. J Med Internet Res. 2019 03 14; 21(3):e10348. PMID: 30869638; PMCID: PMC6437608.
      Citations: 5     Fields:    Translation:Humans
    12. Fu C, Gombos DS, Lee J, George GC, Hess K, Whyte A, Hong DS. Erratum: Ocular toxicities associated with targeted anticancer agents: an analysis of clinical data with management suggestions. Oncotarget. 2019 01 29; 10(9):1011-1013. PMID: 30847029; PMCID: PMC6398178.
      Citations:    Fields:    
    13. George GC, Buford A, Hess K, Piha-Paul SA, Zinner R, Subbiah V, Hinojosa C, Cleeland CS, Meric-Bernstam F, Bernstam EV, Hong DS. Cancer-Related Internet Use and Online Social Networking Among Patients in an Early-Phase Clinical Trials Clinic at a Comprehensive Cancer Center. JCO Clin Cancer Inform. 2018 12; 2:1-14. PMID: 30652565; PMCID: PMC6874009.
      Citations: 3     Fields:    Translation:Humans
    14. Kehl KL, Fullmer CP, Fu S, George GC, Hess KR, Janku F, Karp DD, Kato S, Kizer CK, Kurzrock R, Naing A, Pant S, Piha-Paul SA, Subbiah V, Tsimberidou AM, Hong DS. Insurance Clearance for Early-Phase Oncology Clinical Trials Following the Affordable Care Act. Clin Cancer Res. 2017 Aug 01; 23(15):4155-4162. PMID: 28729355; PMCID: PMC5902668.
      Citations: 1     Fields:    
    15. Fu C, Gombos DS, Lee J, George GC, Hess K, Whyte A, Hong DS. Ocular toxicities associated with targeted anticancer agents: an analysis of clinical data with management suggestions. Oncotarget. 2017 Aug 29; 8(35):58709-58727. PMID: 28938590; PMCID: PMC5601686.
      Citations: 8     Fields:    
    16. George GC, Iwuanyanwu EC, Anderson KO, Yusuf A, Zinner RG, Piha-Paul SA, Tsimberidou AM, Naing A, Fu S, Janku F, Subbiah V, Cleeland CS, Mendoza TR, Hong DS. Sleep quality and its association with fatigue, symptom burden, and mood in patients with advanced cancer in a clinic for early-phase oncology clinical trials. Cancer. 2016 Nov 15; 122(21):3401-3409. PMID: 27412379.
      Citations: 12     Fields:    Translation:Humans
    17. Hong DS, Kurzrock R, Falchook GS, Andresen C, Kwak J, Ren M, Xu L, George GC, Kim KB, Nguyen LM, O'Brien JP, Nemunaitis J. Phase 1b study of lenvatinib (E7080) in combination with temozolomide for treatment of advanced melanoma. Oncotarget. 2015 Dec 15; 6(40):43127-34. PMID: 26503473; PMCID: PMC4767496.
      Citations: 10     Fields:    Translation:HumansCTClinical Trials
    18. Vishnoi M, Peddibhotla S, Yin W, T Scamardo A, George GC, Hong DS, Marchetti D. The isolation and characterization of CTC subsets related to breast cancer dormancy. Sci Rep. 2015 Dec 03; 5:17533. PMID: 26631983; PMCID: PMC4668355.
      Citations: 54     Fields:    Translation:HumansCells
    19. Hong DS, Kurzrock R, Wheler JJ, Naing A, Falchook GS, Fu S, Kim KB, Davies MA, Nguyen LM, George GC, Xu L, Shumaker R, Ren M, Mink J, Bedell C, Andresen C, Sachdev P, O'Brien JP, Nemunaitis J. Phase I Dose-Escalation Study of the Multikinase Inhibitor Lenvatinib in Patients with Advanced Solid Tumors and in an Expanded Cohort of Patients with Melanoma. Clin Cancer Res. 2015 Nov 01; 21(21):4801-10. PMID: 26169970; PMCID: PMC4840931.
      Citations: 24     Fields:    Translation:HumansCTClinical Trials
    20. Hong DS, Garrido-Laguna I, Ekmekcioglu S, Falchook GS, Naing A, Wheler JJ, Fu S, Moulder SL, Piha-Paul S, Tsimberidou AM, Wen Y, Culotta KS, Anderes K, Davis DW, Liu W, George GC, Camacho LH, Percy Ivy S, Kurzrock R. Dual inhibition of the vascular endothelial growth factor pathway: a phase 1 trial evaluating bevacizumab and AZD2171 (cediranib) in patients with advanced solid tumors. Cancer. 2014 Jul 15; 120(14):2164-73. PMID: 24752867.
      Citations: 10     Fields:    Translation:HumansCellsCTClinical Trials
    21. Hong DS, George GC, Iwuanyanwu EC, Tavana B, Falchook GS, Piha-Paul SA, Wheler JJ, Mistry RH, Lei X, Kurzrock R. Factors related to biopsy willingness in patients with advanced cancer in a phase 1 clinic for molecularly targeted therapy. J Cancer Res Clin Oncol. 2013 Jun; 139(6):963-70. PMID: 23455881.
      Citations: 3     Fields:    Translation:Humans
    22. Hong DS, Banerji U, Tavana B, George GC, Aaron J, Kurzrock R. Targeting the molecular chaperone heat shock protein 90 (HSP90): lessons learned and future directions. Cancer Treat Rev. 2013 Jun; 39(4):375-87. PMID: 23199899.
      Citations: 100     Fields:    Translation:Humans
    23. Hong DS, Choe JH, Naing A, Wheler JJ, Falchook GS, Piha-Paul S, Moulder SL, George GC, Choe JM, Strauss LC, Gallick GE, Kurzrock R. A phase 1 study of gemcitabine combined with dasatinib in patients with advanced solid tumors. Invest New Drugs. 2013 Aug; 31(4):918-26. PMID: 23179336; PMCID: PMC4482128.
      Citations: 18     Fields:    Translation:HumansCellsCTClinical Trials
    24. Hong DS, Bowles DW, Falchook GS, Messersmith WA, George GC, O'Bryant CL, Vo AC, Klucher K, Herbst RS, Eckhardt SG, Peterson S, Hausman DF, Kurzrock R, Jimeno A. A multicenter phase I trial of PX-866, an oral irreversible phosphatidylinositol 3-kinase inhibitor, in patients with advanced solid tumors. Clin Cancer Res. 2012 Aug 01; 18(15):4173-82. PMID: 22693357.
      Citations: 68     Fields:    Translation:HumansCTClinical Trials
    25. Schiefelbein EL, Mirchandani GG, George GC, Becker EA, Castrucci BC, Hoelscher DM. Association between depressed mood and perceived weight in middle and high school age students: Texas 2004-2005. Matern Child Health J. 2012 Jan; 16(1):169-76. PMID: 21165762.
      Citations: 10     Fields:    Translation:Humans
    26. George GC, Springer AE, Forman MR, Hoelscher DM. Associations among dietary supplement use and dietary and activity behaviors by sex and race/ethnicity in a representative multiethnic sample of 11th-grade students in Texas. J Am Diet Assoc. 2011 Mar; 111(3):385-93. PMID: 21338737.
      Citations: 7     Fields:    Translation:Humans
    27. George GC, Hoelscher DM, Nicklas TA, Kelder SH. Diet- and body size-related attitudes and behaviors associated with vitamin supplement use in a representative sample of fourth-grade students in Texas. J Nutr Educ Behav. 2009 Mar-Apr; 41(2):95-102. PMID: 19304254; PMCID: PMC5019536.
      Citations: 1     Fields:    Translation:Humans
    28. George GC, Hanss-Nuss H, Milani TJ, Freeland-Graves JH. Food choices of low-income women during pregnancy and postpartum. J Am Diet Assoc. 2005 Jun; 105(6):899-907. PMID: 15942539.
      Citations: 28     Fields:    Translation:HumansAnimals
    29. George GC, Milani TJ, Hanss-Nuss H, Freeland-Graves JH. Compliance with dietary guidelines and relationship to psychosocial factors in low-income women in late postpartum. J Am Diet Assoc. 2005 Jun; 105(6):916-26. PMID: 15942541.
      Citations: 38     Fields:    Translation:Humans
    30. The isolation and characterization of CTC subsets related to breast cancer dormancy. Scientific Reports. 5.
    31. Targets by organ site.
    32. Targets by organ site.
    33. Phase 1b study of lenvatinib (E7080) in combination with temozolomide for treatment of advanced melanoma. Oncotarget. 6:43127-43134.
    34. Targets by organ site.
    35. Targets by organ site.
    36. Retreatment with anti-EGFR based therapies in metastatic colorectal cancer. BMC Cancer. 15.
    37. Targets by organ site.
    38. Sleep quality and its association with fatigue, symptom burden, and mood in patients with advanced cancer in a clinic for early-phase oncology clinical trials. Cancer. 122:3401-3409.
    39. Development and validation of a semi-quantitative food frequency questionnaire for young adult women in the southwestern United States. Nutrition Research. 24:29-43.
    40. Phase I dose-escalation study of the multikinase inhibitor lenvatinib in patients with advanced solid tumors and in an expanded cohort of patients with melanoma. Clinical Cancer Research. 21:4801-4810.
    GEORGE's Networks
    Click the
    Explore
    buttons for more information and interactive visualizations!
    Concepts (164)
    Explore
    _
    Co-Authors (24)
    Explore
    _
    Similar People (60)
    Explore
    _
    Same Department Expand Description
    Explore
    _